Freienbach, Switzerland (ots) - EffRx Pharmaceuticals SA is proud to announce that BINOSTO (TM) (alendronate sodium) Effervescent Tablet for buffered oral solution (70 mg) is now available by prescription in the United States. The U.S. Food and Drug Administration earlier this year approved BINOSTO to treat ...
Freienbach, Switzerland (ots) - EffRx Pharmaceuticals SA is proud to announce and welcome Lorenzo Bosisio, new Head of Business Development and Marketing. Lorenzo will be responsible for the outlicensing and marketing of EffRx's approved product Steovess®/BinostoTM outside of the USA and Canada as well as developing the business for EffRx's other pipeline products. ...
Epalinges (ots) - EffRx Pharmaceuticals SA, an Epalinges/Lausanne, Switzerland based drug delivery company, announces that US patent 7,964,212 was issued on June 21, 2011, enhancing the protection of EX101. This patent grants significant additional Intellectual Property concerning the EffRx Lead Program, EX101 (70 ...